Distinct genetic changes characterise multifocality and diverse histological subtypes in papillary thyroid carcinoma

Pathology

Volumn 42, Issue 6, 2010, Pages 524-533

  Jovanovic, Lidija ^a   Delahunt, Brett ^a   McIver, Bryan ^c   Eberhardt, Norman L ^c,d   Bhattacharya, Alokananda ^b   Lea, Rod ^b   Grebe, Stefan K G ^c  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b INSTITUTE OF ENVIRONMENTAL SCIENCE AND RESEARCH   (New Zealand)

^c MAYO CLINIC   (United States)

^d MAYO GRADUATE SCHOOL   (United States)

Author keywords

Allelic imbalances; Loss of heterozygosity; Multifocal papillary thyroid carcinoma; Phenotypic diversity

Indexed keywords

EID: 77956921006     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.3109/00313025.2010.508780     Document Type: Article

References (48)

1. Russell WO, Ibanez ML, Clark RL, White EC. Thyroid carcinoma. Classification, intraglandular dissemination, and clinicopathological study based upon whole organ sections of 80 glands. Cancer 1963; 16: 1425-1460
2. Katoh R, Sasaki J, Kurihara H, et al. Multiple thyroid involvement (intraglandular metastasis) in papillary thyroid carcinoma. A clinicopathologic study of 105 consecutive patients. Cancer 1992; 70: 1585-1590
3. Jovanovic L, Delahunt B, McIver M, Eberhardt NL, SK Grebe. Most multifocal papillary thyroid carcinomas acquire genetic and morphotype diversity through subclonal evolution following the intra-glandular spread of the initial neoplastic clone. J Pathol 2008; 215: 145-154
4. De Lellis RA, Lloyd RA, Heitz PU, Eng C, editors. Pathology and Genetics of Tumours of Endocrine Organs. World Health Organization Classification of Tumours. Lyon: International Agency for Research on Cancer, 2004; 320.
5. Trovisco V, Vieira de Castro I, Soares P, et al. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol 2004; 202: 247-251
6. Wreesmann VB, Ghossein RA, Hazel M, et al. Follicular variant of papillary thyroid carcinoma: genome-wide appraisal of a controversial entity. Genes Chromosomes Cancer 2004; 40: 355-364
7. Sobrinho-Simoes M, Preto A, Rocha AS, et al. Molecular pathology of well-differentiated thyroid carcinomas. Virchows Arch 2005; 447: 787-793
8. Baloch ZW, LiVolsi VA. Etiology and significance of the optically clear nucleus. Endocr Pathol 2002; 13: 289-299
9. Prendiville S, Burman KD, Ringel MD, et al. Tall cell variant: an aggressive form of papillary thyroid carcinoma. Otolaryngol Head Neck Surg 2000; 122: 352-357
10. Salajegheh A, Petcu EB, Smith RA, Lam AK. Follicular variant of papillary thyroid carcinoma: a diagnostic challenge for clinicians and pathologists. Postgrad Med J 2008; 84: 78-82.
11. Dietmaier W, Hartmann A, Wallinger S, et al. Multiple mutation analyses in single tumor cells with improved whole genome amplification. Am J Pathol 1999; 154: 83-95.
12. Vogelstein B, Fearon ER, Kern SE, et al. Allelotype of colorectal carcinomas. Science 1989; 244: 207-211
13. Herrmann MA, Hay ID, Bartelt DJ, et al. Cytogenetic and molecular genetic studies of follicular and papillary thyroid cancers. J Clin Invest 1991; 88: 1596-1604
14. Califano JA, Johns MM 3rd, Westra WH, et al. An allelotype of papillary thyroid cancer. Int Cancer 1996; 69: 442-444
15. Ward LS, Brenta G, Medvedovic M, Fagin JA. Studies of allelic loss in thyroid tumors reveal major differences in chromosomal instability between papillary and follicular carcinomas. J Clinl Endocrinol Metabol 1998; 83: 525-530
16. Kitamura Y, Shimizu K, Tanaka S, Ito K, Emi M. Association of allelic loss on 1q, 4p, 7q, 9p, 9q, and 16q with postoperative death in papillary thyroid carcinoma. Clin Cancer Res 2000; 6: 1819-1825
17. Girard L, Zöchbauer-Müller S, Virmani AK, Gazdar AF, Minna JD. Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer Res 2000; 60: 4894-4906
18. Soares P, dos Santos NR, Seruca R, Lothe RA, Sobrinho-Simöes M. Benign and malignant thyroid lesions show instability at microsatellite loci. Eur J Cancer 1997; 33: 293-296
19. Lazzereschi D, Palmirotta R, Ranieri A, et al. Microsatellite instability in thyroid tumours and tumour-like lesions. Br J Cancer 1999; 79: 340-345
20. Rodrigues-Serpa A, Catarino A, Soares J. Loss of heterozygosity in follicular and papillary thyroid carcinomas. Cancer Genetics Cytogenetics 2003; 141: 26-31.
21. Zou M, Shi Y, Farid NR, al-Sediary ST, Paterson MC. FHIT gene abnormalities in both benign and malignant thyroid tumours. Eur J Cancer 1999; 35: 467-472
22. McCarthy RP, Wang M, Jones TD, Strate RW, Cheng L. Molecular evidence for the same clonal origin of multifocal papillary thyroid carcinomas. Clin Cancer Res 2006; 12: 2414-2418
23. Chatterjee A, Pulido HA, Koul S, et al. Mapping the sites of putative tumor suppressor genes at 6p25 and 6p21.3 in cervical carcinoma: occurrence of allelic deletions in precancerous lesions. Cancer Res 2001; 61: 2119-2123
24. Kawana Y, Ichikawa T, Suzuki H, et al. Loss of heterozygosity at 7q31.1 and 12p13-12 in advanced prostate cancer. Prostate 2002; 53: 60-64
25. Beder LB, Gunduz M, Ouchida M, et al. Genome-wide analyses on loss of heterozygosity in head and neck squamous cell carcinomas. Lab Invest 2003; 83: 99-105.
26. Narayan G, Pulido HA, Koul S, Lu XY, et al. Genetic analysis identifies putative tumor suppressor sites at 2q35-q36.1 and 2q36.3-q37.1 involved in cervical cancer progression. Oncogene 2003; 22: 3489-3499
27. Stoehr R, Wissmann C, Suzuki H, et al. Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. Lab Invest 2004; 84: 465-478
28. Wan J, Li H, Li Y, Zhu ML, Zhao P. Loss of heterozygosity of Kras2 gene on 12p12-13 in Chinese colon carcinoma patients. World J Gastroenterol 2006; 12: 1033-1037
29. Zedenius J, Vallin G, Svensson A, et al. Allelotyping of follicular thyroid tumors. Hum Genetics 1995; 96: 27-32.
30. Segev DL, Saji M, Phillips GS, et al. Polymerase chain reaction-based microsatellite polymorphism analysis of follicular and Hurthle cell neoplasms of the thyroid. J Clin Endocrinol Metab 1998; 83: 2036-2042
31. Wreesmann VB, Sieczka EM, Socci ND, et al. Genome-wide profiling of papillary thyroid cancer identifies MUCI as an independent prognostic marker. Cancer Res 2004; 64: 3780-3789
32. Padalecki SS, Troyer DA, Hansen MF, et al. Identification of two distinct regions of allelic imbalance on chromosome 18q in metastatic prostate cancer. Int Cancer 2000; 85: 654-658
33. Yashiro M, Carethers JM, Laghi L, et al. Genetic pathways in the evolution of morphologically distinct colorectal neoplasms. Cancer Res 2001; 61: 2676-2683
34. Powell CA, Bueno R, Borczuk AC, et al. Patterns of allelic loss differ in lung adenocarcinomas of smokers and nonsmokers. Lung Cancer 2003; 39: 23-29 (Pubitemid 36020291)
35. Sunamura M, Lefter LP, Duda DG, et al. The role of chromosome 18 abnormalities in the progression of pancreatic adenocarcinoma. Pancreas 2004; 28: 311-316
36. Takebayashi S, Hickson A, Ogawa T, et al. Loss of chromosome arm 18q with tumor progression in head and neck squamous cancer. Genes Chromosomes Cancer 2004; 41: 145-154
37. Lin X, Finkelstein S, Zhu B, Silverman J. Molecular analysis of multifocal papillary thyroid carcinoma. J Mol Endocrinol 2008; 41: 195-203.
38. Machens A, Holzhausen HJ, Lautenschläger C, Dralle H. The tall-cell variant of papillary thyroid carcinoma: a multivariate analysis of clinical risk factors. Arch Surg 2004; 389: 278-282
39. Grebe SK, McIver B, Hay ID, et al. Frequent loss of heterozygosity on chromosomes 3p and 17p without VHL or p53 mutations suggests involvement of unidentified tumor suppressor genes in follicular thyroid carcinoma. J Clin Endocrinol Metab 1997; 82: 3684-3691
40. Kitamura Y, K Shimizu, Tanaka S, Ito K, Emi M. Allelotyping of anaplastic thyroid carcinoma: frequent allelic losses on 1q, 9p, 11, 17, 19p, and 22q, Genes. Chromosomes Cancer 2000; 27: 244-251
41. Kitamura Y, Shimizu K, Tanaka S, Ito K, Emi M. Allelotyping of follicular thyroid carcinoma: frequent allelic losses in chromosome arms 7q, 11p, and 22q. J Clin Endocrinol Metab 2001; 86: 4268-4272
42. Rodrigues RF, Roque L, Rosa-Santos J, Cid O, Soares J. Karyotypic characterization of papillary thyroid carcinomas. Cancer 2001; 92: 2529-2538
43. Rodrigues RF, Roque L, Rosa-Santos J, Cid O, Soares J. Chromosomal imbalances associated with anaplastic transformation of follicular thyroid carcinomas. Br J Cancer 2004; 90: 492-496
44. Giannini R, Ugolini C, Lupi C, et al. The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma. J Clin Endocrinol Metab 2007; 92: 3511-3516
45. Hittelman WN. Genetic instability in epithelial tissues at risk for cancer. Ann Sci 2001; 952: 1-12.
46. Tabor MP, Brakenhoff RH, vanHouten VM, et al. Persistence of genetically altered fields in head and neck cancer patients: biological and clinical implications. Clin Cancer Res 2001; 7: 1523-1532.
47. Fukino K, Shen L, Matsumoto S, et al. Combined total genome loss of heterozygosity scan of breast cancer stroma and epithelium reveals multiplicity of stromal targets. Cancer Res 2004; 64: 7231-7236
48. Braakhuis BJ, Leemans CR, Brakenhoff RH. Using tissue adjacent to carcinoma as a normal control: an obvious but questionable practice. J Pathol 2004; 203: 620-621